Latest News

STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t

A pretty impressive result from ASCO that’s also being published in the New England Journal of Medicine: Kisqali, a breast cancer drug from Novartis (NVS), dramatically extended survival in younger women who developed the most common form of breast cancer.

In women with hormone receptor positive/HER2 negative breast cancer who were premenopausal, adding Kisqali to hormone-blocking therapy resulted in a 29% reduction in the risk of death. After three and a half years, that translates into 70% of the women who got the combination being alive, compared to 42% of those who got the standard therapy. That’s a dramatic improvement in a disease where it is often hard to prove a survival benefit.

Continue to STAT Plus to read the full story…

Source link

Related posts

Medical News Today: Celiac disease may be treated with cystic fibrosis drugs


Riassunto: L'ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) approva HEMLIBRA® di Chugai per il trattamento dell'emofilia A senza inibitori


Scientists reveal how DNA damage leads to cancer and hereditary diseases


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy